[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354789-105":59,"doc-detail-354789-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","development-of-tri-cistronic-cldn182-car-t-cells-incorporating-pd-1cd28-switch-and-cyclophilin-a-for-enhanced-solid-tumor-immunotherapy","Development of tri-cistronic CLDN18.2 CAR-T cells incorporating PD-1/CD28 switch and cyclophilin A for enhanced solid tumor immunotherapy","","CAR-T cell therapy offers substantial promise against solid tumors, yet immune suppression and tumor-specific barriers restrict effectiveness. This study develops a tri-cistronic CLDN18.2-directed CAR-T platform by integrating a PD-1/CD28 chimeric switch receptor with cyclophilin A (CypA) to relieve PD-1-mediated immunosuppression while strengthening T-cell activation and persistence. Tri-cistronic constructs show increased cytokine secretion, improved cytotoxicity in vitro, and enhanced antitumor efficacy with sustained regression in xenograft models, with no observable toxicity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-of-tri-cistronic-cldn182-car-t-cells-incorporating-pd-1cd28-switch-and-cyclophilin-a-for-enhanced-solid-tumor-immunotherapy/354789/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-of-tri-cistronic-cldn182-car-t-cells-incorporating-pd-1cd28-switch-and-cyclophilin-a-for-enhanced-solid-tumor-immunotherapy/354789.png","ImageObject",300,407,{"name":92,"@type":93},"MrHarris58","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the tri-cistronic CLDN18.2 CAR-T design aim to solve?","Question",{"text":112,"@type":113},"It targets immune suppression and tumor-specific barriers that limit CAR-T activity in solid tumors, especially PD-1-mediated immunosuppression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What key components are integrated into the tri-cistronic CAR-T platform?",{"text":117,"@type":113},"The platform combines a PD-1/CD28 chimeric switch receptor with cyclophilin A (CypA), and includes CLDN18.2-directed CAR targeting.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports the enhanced performance of these CAR-T cells?",{"text":121,"@type":113},"In vitro assays show higher cytokine secretion and stronger cytotoxicity against CLDN18.2-positive gastric cancer cells, while in vivo xenograft models demonstrate superior antitumor efficacy and sustained tumor regression without observable toxicity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354789,1790380884,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687212988360,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Full article  \nJournal of Microbiology Vol. 64, No. 1, e2510017 [https://doi.org/10.71150/jm.2510017](https://doi.org/10.71150/jm.2510017)  \npISSN 1225–8873 • eISSN 1976–3794  \nReceived: October 22, 2025  \nRevised: December 8, 2025  \nAccepted: December 9, 2025  \nPublished online: January 31, 2026  \n*Correspondence  \nHeon Ju Lee  \n[leehj2014@naver.com](leehj2014@naver.com)  \nDevelopment of tri-cistronic CLDN18.2 CAR-T cells incorporating PD-1/CD28 switch and cyclophilinA for enhanced solid tumor immunotherapy  \nHeon Ju Lee1,*, Seo Jin Hwang1, Eun Hee Jeong1, Mi Hee Chang1, BuYeon Heo1,2, Jaeyul Kwon2, Yoona Noh3, Jihoon Nah3,4  \n1CARBio Therapeutics Co., Ltd., Cheongju 28160, Republic of Korea  \n2Translational Immunology Institute, Department of Medical Education, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea  \n3Department of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju 28644, Republic of Korea  \n4Department of Biochemistry, Chungbuk National University, Cheongju 28644, Republic of Korea  \nChimeric antigen receptor (CAR)-T cell therapy holds significant potential for the treatment of solid tumors. However, immune suppression and tumor-specific barriers limit its application. Claudin 18.2 (CLDN18.2), a gastric lineage-specific tight junction protein highly expressed in gastric and pancreatic cancers, is a promising therapeutic target. In this study, we aimed to develop a next-generation tri-cistronic CLDN18.2-directed CAR-T cell platform that integrates a programmed cell death protein 1 (PD-1)/CD28 chimeric switch receptor with cyclophilin A (CypA). This platform sought to counteract PD-1–mediated immunosuppression and enhance T-cell activation and persistence. We generated CLDN18.2 CAR-T cells incorporating costimulatory inducible T-cell costimulator (ICOS) domains using lentiviral vector-based recombinant engineering. We further evaluated their cytokine release, cytotoxic activity, and safety profiles. In vitro, tri-cistronic CAR-T cells exhibited markedly increased interferon γ and tumor necrosis factor α secretion and enhanced cytotoxicity against CLDN18.2-positive gastric cancer cells compared with conventional CAR-T constructs. In vivo, these cells showed superior antitumor efficacy and sustained tumor regression without observable toxicity in xenograft gastric cancer models. Collectively, these findings demonstrate that the integration of PD-1/CD28 signaling and CypA within a tri-cistronic framework significantly reinforces CAR-T cell functionality and durability. This suggests strong clinical potential as a next-generation immunotherapy for solid tumors.  \nKeywords: tri-cistronic CAR-T cells, Claudin18.2 (CLDN18.2) antigen, PD-1/CD28 chimeric switch receptor, cyclophilin A (CypA), gastric cancer, immune checkpoint modulation  \nIntroduction  \nRecent advances in chimeric antigen receptor (CAR)-T cell therapies have improved outcomes for patients with previously intractable diseases. In particular, considerable remission rates have been observed in patients with hematologic malignancies. The application of these therapies has also expanded to include autoimmune diseases and solid tumors (Baker and June, 2024; Jaspers et al., 2023; June and Sadelain, 2018) . CAR-T technology, which delivers therapeutic genes into T cells via viral vectors, has rapidly progressed from clinical trials to multiple approved therapies worldwide. Thus, it is an excellent candidate for next-generation gene and immune cell therapies (Maus and June, 2016).  \nImmune homeostasis is maintained by a tightly regulated balance between effector function and self-tolerance. Its centrality has been markedly underscored by recent breakthroughs in regulatory T-cell (Treg) biology. The 2025 Nobel Prize in Physiology or Medicine, which honored the discovery ofTregs and identification of FOXP3 as their lineage-defining transcription factor, signified a formal recognition of this paradigm shift ","cbCaicGKHGR9MnWr","https://ap.wps.com/l/cbCaicGKHGR9MnWr","pdf",1989888,"English","# Introduction\n## Background on CAR-T therapy and limitations\n## Targeting solid tumors via CLDN18.2\n## Rationale for PD-1/CD28 switching and CypA integration","[{\"question\":\"What problem does the tri-cistronic CLDN18.2 CAR-T design aim to solve?\",\"answer\":\"It targets immune suppression and tumor-specific barriers that limit CAR-T activity in solid tumors, especially PD-1-mediated immunosuppression.\"},{\"question\":\"What key components are integrated into the tri-cistronic CAR-T platform?\",\"answer\":\"The platform combines a PD-1/CD28 chimeric switch receptor with cyclophilin A (CypA), and includes CLDN18.2-directed CAR targeting.\"},{\"question\":\"What evidence supports the enhanced performance of these CAR-T cells?\",\"answer\":\"In vitro assays show higher cytokine secretion and stronger cytotoxicity against CLDN18.2-positive gastric cancer cells, while in vivo xenograft models demonstrate superior antitumor efficacy and sustained tumor regression without observable toxicity.\"}]","Development of tri-cistronic CLDN18.2 CAR-T cells incorporating PD-1/CD28 switch and cyclophilin A for enhanced solid tumor immunotherapy | PDF",1790113951,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/27a835ba4919e364e6c8a8e3a8da11c4.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69e061abdf0da9bb922d6798e61e7fea.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57521c18b3d2eb031b43c202eb8a7551.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/448cd9f4b64eee03bf53b5330e01646b.webp",980,1306]